Loading people...
Florian Müllershausen is a Managing Director at the Novartis Venture Fund based in Basel, Switzerland. He holds a doctorate from Ruhr University Bochum and a master's equivalent diploma in the natural sciences. Prior to joining the corporate venture fund, he spent over a decade in various scientific, research, and strategic leadership roles within the broader global pharmaceutical industry. In his current capacity, he serves as a board director for multiple portfolio companies and has participated in significant European biotechnology transactions, including the €1.18 billion acquisition of NBE-Therapeutics by Boehringer Ingelheim in 2020. He also represented the fund during the CHF 110 million Series B financing round for Swiss biotech firm Anaveon in 2021. His professional focus centers on utilizing his scientific research background to evaluate, invest in, and build early-stage biotechnology and therapeutics companies.
Florian Müllershausen is a distinguished Managing Director at the Novartis Venture Fund, a leading corporate venture capital firm dedicated to investing in and nurturing innovative life science companies. In this crucial role, Florian is instrumental in shaping the fund's investment strategy, identifying promising startups, and guiding them through their growth phases to bring transformative medical solutions to patients worldwide.
At the Novartis Venture Fund, Florian's investment focus spans a broad spectrum of the life sciences sector. He actively seeks out companies developing novel therapeutics, cutting-edge biotechnologies, and disruptive health technologies. His expertise is particularly valuable in evaluating early-stage opportunities that demonstrate strong scientific merit, significant unmet medical needs, and the potential for substantial impact. The fund's mandate, and by extension Florian's work, is to support ventures that complement Novartis's core research and development areas, including but not limited to oncology, neuroscience, immunology, cardiovascular and metabolic diseases, and gene therapy.
Florian Müllershausen's career background reflects a deep understanding of both scientific innovation and strategic business development within the pharmaceutical and biotech industries. His journey has equipped him with a unique perspective on the challenges and opportunities inherent in translating scientific discoveries into viable commercial products. This blend of scientific acumen and business foresight enables him to effectively assess complex investment proposals and provide invaluable guidance to portfolio companies. He is known for his commitment to fostering entrepreneurship and building strong relationships with founders and scientific leaders.
While specific individual investments are often part of the fund's broader portfolio, Florian plays a key role in the Novartis Venture Fund's overall success in backing companies that have gone on to achieve significant milestones, including successful clinical trials, regulatory approvals, and strategic partnerships. His work contributes directly to the fund's mission of accelerating innovation that can ultimately improve human health. Through his leadership and strategic insights, Florian Müllershausen continues to be a driving force in the life sciences investment landscape, helping to bring forward the next generation of medical breakthroughs.
Florian Müllershausen is a Managing Director at the Novartis Venture Fund, a corporate venture capital arm of Novartis, focusing on early-stage life science investments.
He invests in innovative life science companies, including biotech, pharmaceutical, and health technology firms, across various therapeutic areas that align with Novartis's strategic interests.
Florian Müllershausen works at the Novartis Venture Fund, which is part of the global pharmaceutical company Novartis.
